Veccia, Antonello

Veccia, Antonello  

Centro Interdipartimentale di Scienze Mediche - CI  

Mostra records
Risultati 1 - 16 di 16 (tempo di esecuzione: 0.037 secondi).
Titolo Anno di pubblicazione Autori Unitn File
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer 1-gen-2019 Caffo, OrazioVeccia, Antonello +
Association of G8 screening tool with prognosis and survival in patients with non-small cell lung cancer: A retrospective analysis from a single institution 1-gen-2025 Veccia, AntonelloPontalti, StefanoCaffo, Orazio +
Cardiovascular toxicities of systemic treatments of prostate cancer 1-gen-2017 Veccia, AntonelloCaffo, Orazio +
Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or Enzalutamide 1-gen-2025 Caffo O.Veccia A. +
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial 1-gen-2021 Caffo, O.Veccia, A. +
Docetaxel rechallenge in patients with castration-resistant prostate cancer - A review 1-gen-2012 Caffo OVeccia A. +
Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients 1-gen-2015 Caffo OVeccia A. +
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone 1-gen-2017 Caffo, OrazioVeccia, Antonello +
Modified 3-week schedule of gemcitabine plus cisplatin for non-small cell lung cancer treatment 1-gen-2017 Veccia, AntonelloCaffo, Orazio +
Organized prostate cancer screening program: a proposal from the Italian Society of Urology (SIU) 1-gen-2024 Caffo O.Veccia A. +
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives 1-gen-2025 Veccia, AntonelloCaffo, Orazio +
Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC 1-gen-2025 Veccia A.Caffo O. +
Prognostic Role of Inflammatory and Nutritional Biomarkers in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Alone or in Combination with Chemotherapy as First-Line 1-gen-2024 Veccia, AntonelloCaffo, Orazio +
Prostate cancer: Screening and early detection 1-gen-2024 Caffo, OrazioVeccia, Antonello
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study 1-gen-2022 Veccia, AntonelloCaffo, Orazio +
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone 1-gen-2016 Caffo, OrazioVeccia, Antonello +